Contributions
Abstract: PB2033
Type: Publication Only
Background
Limited stage (Ann Arbor stage 1 or 2) mantle cell lymphoma (MCL) is an extremely rare disease. Thus, there are little data about the clinical feature and treatment outcomes of patients with early stage mantle cell lymphoma.
Aims
The clinical features were reviewed, and the treatment outcomes were analyzed.
Methods
We consecutively collected stage 1 or 2 MCL cases diagnosed between 2000 and 2016 in 16 institutions in CISL group. All patients were pathologically confirmed and received systemic evaluation for staging work-up.
Results
The median age of patients was 66 years (range: 18 – 85 years), male (n=31, 75.6%) was predominant compared to female. The majority of patients (n=28, 68.3%) had stage 2 disease, 29 patients (70.7%) were symptomatic. The elevation of LDH (n=2, 4.9%) was not common, thus, 39 patients (95.1%) had low risk (0 or 1 score) of the International Prognostic Index (IPI), and 28 patients (68.3%) had low risk (1-3 score) of the MIPI. As the first therapeutic strategy, most patients (n=37, 90.1%) received chemotherapy, radiotherapy (n=2), surgical resection (n=1), and no treatment (n=1). Of patients who received chemotherapy, 23 patients (56.9%) were administered with rituximab containing regimen, and R-CHOP (n=17) and R-bendamustine (n=4) was commonly used. The best response rate was 97.4% (n=38) including 32 complete response (78%). In aspect of sites of relapse (n=16), local relapse rate was 31.3% (n=5), distant relapse rate 43.8% (n=7), and local & distant relapse rate 25% (n=4). With the median follow-up duration of 40.6 months, the median relapse free survival was 56.1 months, and the 5-year overall survival rate was 80.4%.
Conclusion
Limited state MCL showed indolent clinical and low risk prognostic features. Chemotherapy could be effective for controlling localized MCL lesion with high complete response rate. Less intensive chemotherapy may be preferred.
Session topic: 20. Indolent Non-Hodgkin lymphoma – Clinical
Abstract: PB2033
Type: Publication Only
Background
Limited stage (Ann Arbor stage 1 or 2) mantle cell lymphoma (MCL) is an extremely rare disease. Thus, there are little data about the clinical feature and treatment outcomes of patients with early stage mantle cell lymphoma.
Aims
The clinical features were reviewed, and the treatment outcomes were analyzed.
Methods
We consecutively collected stage 1 or 2 MCL cases diagnosed between 2000 and 2016 in 16 institutions in CISL group. All patients were pathologically confirmed and received systemic evaluation for staging work-up.
Results
The median age of patients was 66 years (range: 18 – 85 years), male (n=31, 75.6%) was predominant compared to female. The majority of patients (n=28, 68.3%) had stage 2 disease, 29 patients (70.7%) were symptomatic. The elevation of LDH (n=2, 4.9%) was not common, thus, 39 patients (95.1%) had low risk (0 or 1 score) of the International Prognostic Index (IPI), and 28 patients (68.3%) had low risk (1-3 score) of the MIPI. As the first therapeutic strategy, most patients (n=37, 90.1%) received chemotherapy, radiotherapy (n=2), surgical resection (n=1), and no treatment (n=1). Of patients who received chemotherapy, 23 patients (56.9%) were administered with rituximab containing regimen, and R-CHOP (n=17) and R-bendamustine (n=4) was commonly used. The best response rate was 97.4% (n=38) including 32 complete response (78%). In aspect of sites of relapse (n=16), local relapse rate was 31.3% (n=5), distant relapse rate 43.8% (n=7), and local & distant relapse rate 25% (n=4). With the median follow-up duration of 40.6 months, the median relapse free survival was 56.1 months, and the 5-year overall survival rate was 80.4%.
Conclusion
Limited state MCL showed indolent clinical and low risk prognostic features. Chemotherapy could be effective for controlling localized MCL lesion with high complete response rate. Less intensive chemotherapy may be preferred.
Session topic: 20. Indolent Non-Hodgkin lymphoma – Clinical